Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma

This is the authors' abstract. We don't add key points for this paper.

Asthma is a chronic, heterogeneous disease of the airways that involves a multitude of inflammatory processes triggered by various airborne stimuli. Thymic stromal lymphopoietin (TSLP)—an epithelial cell–derived cytokine produced in response to triggers such as allergens, viruses, or pollutants—has a central role in activating and maintaining downstream inflammatory processes in asthma.1 Tezepelumab is an anti-TSLP human monoclonal antibody. In the PATHWAY phase 2b (NCT02054130) and NAVIGATOR phase 3 (NCT03347279) studies, tezepelumab significantly reduced exacerbation rates vs placebo in patients with severe, uncontrolled asthma.